Remove Clinical Research Remove International Remove Pharmacokinetics Remove Regulations
article thumbnail

Where is the promise for plant-based medicines? Part 1: Cannabis  

Drug Discovery World

Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains public scepticism, arguably due to the regulations relating to the substance. Susan Audino is ISO Assessor and Instructor, Scientific Advisor at AOAC International CASP, and Chemistry Laboratory Consultant at SA Audino & Associates, LLC.

article thumbnail

What Does a CRO Actually Do?

Vial

These roles include project managers, research assistants, site contract managers, quality managers, clinical research associates, clinical trial assistants, regulatory affairs managers, heads of clinical operations, data managers, statistical programmers, and biostatisticians.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

The Pharma Data

AMPK is a master regulator of several important metabolic pathways, including lipid metabolism, glucose control and inflammation, and is a novel target for NASH and additional chronic and rare metabolic diseases. Harrison, MD, Director, Summit Clinical Research. NASH Investor Event Information. About PXL770.

Trials 52
article thumbnail

Article FDA Thank You FDA offers a status check on its diversity in research provisions, one year post-FDORA

Agency IQ

FDA offers a status check on its diversity in research provisions, one year post-FDORA At a workshop on FDA’s implementation of new statutory requirements for diversity in clinical research, agency and industry representatives gave a status update on implementation. Policy-wise, this is still a work in progress.

FDA 40
article thumbnail

Global Roundup: EU Approves ViiV’s HIV-1 Drug and More

The Pharma Data

With the integration of both parties’ technologies, BioMedion will provide a new operating system for regulated applications operating effectively on one platform in controlled environments. Following the acquisition, the arivis5D content platform will be rebranded to neuronOS.